4.6 Article

Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation

Journal

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Volume 25, Issue 2, Pages 267-284

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0731-7085(00)00495-7

Keywords

efavirenz; capsule formulation; reverse-phase HPLC; cyano column; separation of double : triple bond homologs

Ask authors/readers for more resources

A stability-indicating high performance liquid chromatographic (HPLC) method was developed for the assay of efavirenz, a non-nucleoside reverse transcriptase inhibitor used in the treatment of AIDS. The HPLC method. which is used to determine potency in efavirenz capsules and related substances in efavirenz drug substance and capsules, was validated per ICH guidelines. This method, which uses a cyano column. is capable of separating efavirenz from its trans-alkene reduction product. This paper will discuss development and validation of this method, which, to the best of our knowledge. is the first known separation of homologs containing double and triple bonds using reverse-phase HPLC. (C) 2001 Dupont Pharmaceutical Company. Published by Elsevier Science B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available